当前位置: X-MOL 学术Bioelectrochemistry › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Aptasensor based on screen-printed electrode for breast cancer detection in undiluted human serum.
Bioelectrochemistry ( IF 5 ) Pub Date : 2020-06-20 , DOI: 10.1016/j.bioelechem.2020.107586
Daísy C Ferreira 1 , Marina R Batistuti 1 , Bassam Bachour 1 , Marcelo Mulato 1
Affiliation  

Breast cancer remains one of the leading causes of women death. The development of more sensitive diagnostic tests, which could present a faster response, lower cost, and could promote early diagnosis would increase the chances of survival. This study reports the development and optimization of an electrochemical aptasensor for the detection of HER2 protein, a breast cancer biomarker. Two sensing platforms were developed on gold screen-printed electrodes. The first platform is composed of self-assembled monolayer (SAM) made from mixture of thiolated DNA aptamers specific for HER2 and 1-mercapto-6-hexanol (MCH), while the second one is a ternary SAM composed of the same aptamer and 1,6-hexanethiol (HDT). Both platforms were further passivated with MCH and blocked with bovine serum albumin. The biosensors were characterized using electrochemical impedance spectroscopy to detect the target protein from 1 pg/mL to 1 μg/mL in phosphate buffered saline, diluted and undiluted human serum through charge transfer resistance value. The ternary SAM architecture shows a reduction of non-specific attachment to the electrode surface due to the HDT antifouling properties. In addition, this platform exhibits 172 pg/mL as limit of detection and a sensitivity of 4.12% per decade for undiluted serum compared with SAM architecture with the 179 pg/mL and 4.32% per decade, respectively. Electrochemical aptasensors are highly promising for medical diagnostic and ternary layers could improve the limit of detection.



中文翻译:

基于丝网印刷电极的Aptasensor在未稀释的人血清中检测乳腺癌。

乳腺癌仍然是导致妇女死亡的主要原因之一。开发更敏感的诊断测试可以提高反应速度,降低成本,并能促进早期诊断,从而增加生存机会。这项研究报告了电化学适体传感器的开发和优化,用于检测乳腺癌生物标志物HER2蛋白。在金丝网印刷电极上开发了两个传感平台。第一个平台由自组装的单分子层(SAM)组成,该分子由对HER2和1-巯基-6-己醇(MCH)特异的硫醇化DNA适体的混合物制成,而第二个平台是由相同的适体和1组成的三元SAM。 ,6-己硫醇(HDT)。将两个平台进一步用MCH钝化,并用牛血清白蛋白封闭。使用电化学阻抗谱对生物传感器进行表征,以通过电荷转移电阻值在磷酸盐缓冲液,稀释和未稀释的人血清中检测从1 pg / mL到1μg/ mL的目标蛋白。由于具有HDT防污性能,三元SAM体系结构显示出非特异性附着在电极表面的现象减少了。此外,与SAM结构相比,该平台的未检测血清检测限为172 pg / mL,每十年的灵敏度为4.12%,每十年分别为179 pg / mL和4.32%。电化学适体传感器在医学诊断中非常有前途,三元层可以提高检测限。通过电荷转移电阻值稀释和稀释未稀释的人血清。由于具有HDT防污性能,三元SAM体系结构显示出非特异性附着在电极表面的现象减少了。此外,与SAM结构相比,该平台的未检测血清检测限为172 pg / mL,每十年的灵敏度为4.12%,每十年分别为179 pg / mL和4.32%。电化学适体传感器在医学诊断中非常有前途,三元层可以提高检测限。通过电荷转移电阻值稀释和稀释未稀释的人血清。由于具有HDT防污性能,三元SAM体系结构显示出非特异性附着在电极表面的现象减少了。此外,与SAM结构相比,该平台的未检测血清检测限为172 pg / mL,每十年的灵敏度为4.12%,每十年分别为179 pg / mL和4.32%。电化学适体传感器在医学诊断中非常有前途,三元层可以提高检测限。与SAM架构相比,未稀释的血清每十年10%,分别为179 pg / mL和4.32%。电化学适体传感器在医学诊断中非常有前途,三元层可以提高检测限。与SAM架构相比,未稀释的血清每十年10%,分别为179 pg / mL和4.32%。电化学适体传感器在医学诊断中非常有前途,三元层可以提高检测限。

更新日期:2020-06-20
down
wechat
bug